Purpose of review The current review provides an update focused on the evolving epidemiology of neonatal abstinence syndrome (NAS), factors influencing disease expression, advances in clinical assessment of withdrawal, novel approaches to NAS treatment, and the emerging role of quality improvement in assessment and management of NAS.
INTRODUCTION
Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome exhibited by some opioid-exposed infants that is characterized by hyperactivity of the central and autonomic nervous system and gastrointestinal tract. Over the last 2 decades, the US incidence of NAS has sharply increased from 1.19 per 1000 hospital births in 2000, to 5 .63 in 2012. During the same time period, the number of infants treated for the syndrome in US neonatal ICUs increased five-fold [1, 2] . Although NAS has been described in the medical literature for several decades [3] , factors that modulate disease expression and severity remain poorly defined. As a result, clinical uncertainty exists about which opioid-exposed infants will develop withdrawal. Further, variation in healthcare settings and interventions used for treatment are widespread across the United States [4] [5] [6] . Given the significant healthcare utilization [2] and the tremendous economic burden [7 & ] associated with NAS, there is a need to understand better the factors that modify disease expression and describe best practices to identify and treat NAS. This review will address the changing epidemiology of NAS, factors that influence disease expression, strategies to identify and treat NAS, and emerging data on the importance of standardizing care for affected infants.
CHANGING EPIDEMIOLOGY
Opioids are the most common illicit substance for which pregnant women seek treatment [ ] detailed state-specific NAS incidence rates per 1000 hospital births in 2013. They found NAS incidence of 0.7 in Hawaii compared with 33.4 in West Virginia. This striking difference has notable implications for the expected healthcare needs of a given population and may help focus primary prevention (e.g., limits to opioid prescribing) and treatment expansion efforts in areas most affected by this epidemic. To garner more timely data for NAS, many states, including Florida, Georgia, Kentucky, and Tennessee, made the syndrome a publicly reportable condition, allowing for improved public health surveillance and targeted response [10 & ]. In some states (e.g., Tennessee), web-based reporting portals have emerged as a tool to provide real-time data on NAS.
POLYSUBSTANCE EXPOSURE AND DISEASE SEVERITY
Predicting which opioid-exposed infants will manifest clinical signs of withdrawal is difficult. Recently, antenatal polysubstance exposure and genetic polymorphisms have emerged as key factors that may affect an infant's risk for developing NAS. Improved understanding of these factors may allow for stratification of infants into categories of risk that would enable individualized observation and treatment plans [13, 14] .
Huybrechts et al. [15 && ] used a national sample of over 200 000 publically insured pregnant women to investigate the impact of in-utero coexposure to psychotropic medications and opioids on the incidence and severity of neonatal drug withdrawal. They observed that the risk of NAS increased 30-60% with coexposure to antidepressants, benzodiazepines, and gabapentin. In this report, coexposure to atypical antipsychotics or nonbenzodiazepine hypnotics (e.g., zolpidem) did not significantly increase the risk of withdrawal. Because the rate of psychotropic medication use in women who use opioids is high, this work may have immediate clinical applicability.
In addition to high rates of psychotropic medication use among pregnant women, rates of marijuana use are also high. Marijuana is the most commonly used illicit drug in pregnancy [16] , and the role of coexposure on modifying NAS expression and severity is unclear. O'Connor et al. [17 & ] performed a retrospective study of nearly 200 maternal-infant dyads in which the mother was maintained on buprenorphine and had marijuana exposure during the third trimester. The likelihood of an infant requiring pharmacologic treatment for NAS (27.6% in marijuana-exposed vs. 15.7% in nonmarijuana-exposed infants, P ¼ 0.66) or duration of infant hospital stay (7.7 days in marijuana exposed vs. 6.6 days in nonexposed infants, P ¼ 0.53) were not significantly associated with marijuana exposure.
GENETIC MEDIATORS OF DISEASE SEVERITY
In adults, single-nucleotide polymorphisms (SNPs) in the mu-opioid receptor (OPRM1), multidrug resistance (ABCB1), and catechol-o-methyltransferase (COMT) genes are associated with risk for opioid addiction. Similarly, one recent report found that OPRM1 and COMT SNPs in newborns were associated with prolonged hospital length of stay(LOS) and treatment for NAS [18] . In addition, a recent pilot study of 21 methadone exposed newborns and their mothers by Mactier et al. [19 & ] found that infants treated for NAS were significantly more likely to carry the homozygous allele of the CYP2B6 gene that encodes a cytochrome P450 monooxygenase enzyme and is present in 75% of the white population. Recent advances in understanding how genomic variation and differential antenatal exposures contribute to NAS risk, and severity may lead to tailored approaches to infant treatment based upon individual risk profiles.
KEY POINTS
Polysubstance exposure and specific genetic polymorphisms influence severity of NAS and should be considered when designing clinical prediction tools aimed at personalizing the care of infants with NAS. When opioid exposed infants are assessed for withdrawal, use of tools that focus on clinically relevant infant characteristics may drastically reduce the number of infants treated pharmacologically for NAS.
In one trial, buprenorphine treatment for NAS results in shorter duration of treatment and length of hospital stay than morphine making it a promising new therapy for NAS.
State-based data is key to identify the changing epidemiology of NAS and provides the necessary framework for policy, public health, and clinical interventions.
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CLINICAL PREDICTION TOOLS FOR NEONATAL ABSTINENCE SYNDROME
Identification of specific factors that lead to NAS enabled the development of clinical prediction tools for NAS. One example is a 'symptoms only tool' created by Isemann et al. [20 & ] intended to predict the need for pharmacologic treatment for NAS within 2 days of birth. Based on data from a retrospective analysis of 264 infants with in-utero exposure to opioids, the authors designed a clinical prediction tool based upon on three highly predictive clinical signs associated with the need for pharmacotherapy to treat NAS: increased muscle tone, tremors when disturbed, and excoriation. The current American Academy of Pediatrics (AAP) guideline recommends 3 days of observation for short-acting opioids and 5-7 days for longer acting opioids [6] . NAS prediction tools, such as the one designed by Isemann et al., may expedite treatment decisions in at-risk infants and optimize healthcare utilization for those who are thought to be at low risk for withdrawal.
IDENTIFICATION OF NEONATAL ABSTINENCE SYNDROME: WHAT TOOL TO USE?
The approach to how and where in a hospital [e.g., newborn nursery, mother's room, neonatal ICU (NICU)] infants are evaluated for signs of withdrawal is not standardized [21, 22] . A modified version of the Finnegan Neonatal Abstinence Scoring System (FNASS) is the most commonly used tool to assess newborns for signs of withdrawal [21] . The FNASS assigns a numerical score to 21 subjective clinical signs of NAS to determine NAS severity and is used to guide pharmacological treatment. Notably, the tool has not been validated to show utility in improving outcomes for infants with NAS [6] . In an alternative approach that focused on a small number of clinically relevant factors, Grossman et al. [23 && ] describe novel criteria for the clinical assessment of infants with NAS, developed as part of a single-center quality improvement project to improve care of substance exposed infants. This functional assessment used three parameters: the infant's ability to eat, to sleep, and to be consoled. If the infant was able to be breastfed or take more than 1 ounce from a bottle per feed, to sleep undisturbed for at least 1 h, and could be consoled within 10 min if crying, pharmacologic treatment with morphine was not started or increased regardless of other signs of withdrawal. This intervention, along with others in the project, significantly reduced the proportion of methadoneexposed infants treated with morphine from 98 to 14%. Grossman et al. suggest that the FNASS-guided approach to treating NAS encourages providers to treat a number and not a patient, and call for change in practice to the assessment of withdrawal signs [24 & ]. In another quality improvement effort, Holmes et al. [25 && ] describe an 'infant-centered scoring' protocol in which the infants were scored only after ondemand feeds during skin-to-skin care. This modification aimed to avoid waking infants from sleep for scoring, removing them from family members' arms to be assessed, and assigning points to infants for crying when hungry. Although these innovations await rigorous evaluation and validation, they demonstrate that quality improvement methodology plays a promising role in reducing the number of infants exposed to opioid treatment for NAS.
WHERE TO TREAT NEONATAL ABSTINENCE SYNDROME
Newborn infants with NAS are treated and observed in a variety of hospital settings including newborn nursery, inpatient pediatric wards, and NICU. Although a NICU setting provides the highest level of acute care, this setting may separate the maternalinfant dyad and create barriers to breastfeeding and rooming, which in turn may increase length of treatment and hospital stay for NAS [26, 27] . Holmes et al. ] retrospectively assessed the impact of parental presence at the bedside among 86 mother-infant pairs. They found in adjusted analyses that parental presence was significantly associated with 5.7 fewer days (P ¼ 0.03) of opioid therapy for NAS and a trend toward shorter LOS by more than 5 days (P ¼ 0.9). In addition, maximal parental presence was associated with reduced opioid treatment days. These data suggest that strategies that promote rooming-in and minimize the separation of the maternal-infant dyad hold promise as nonpharmacologic treatment for NAS. When family or maternal presence is limited, using volunteers to provide comfort to infants with NAS may be a reasonable alternative [25 && ]. As hospital systems strategize where opioid exposed infants will be observed and treated, priority should be placed on keeping the maternal-infant dyad together.
PHARMACOLOGIC TREATMENT OF NEONATAL ABSTINENCE SYNDROME
Infants with NAS are often treated pharmacologically, and morphine is the most frequent opioid used to treat NAS [29 & ]. New evidence suggests that buprenorphine, a partial mu opioid receptor agonist and full kappa opioid receptor antagonist successfully used in adults to treat opioid withdrawal, may be a better alternative in infants [30 && ]. In the Blinded Buprenorphine or Neonatal Morphine Solution trial, a single-site randomized double-masked, doubledummy trial, sublingual buprenorphine was compared with oral morphine in 63 infants with NAS. They found that both the median duration of treatment [15 vs . 28 days, difference 13 days, 95% confidence interval (CI) 7-21 days; P < 0.001] and the median length of hospital stay (21 vs. 33 days, difference 12 days, 95% CI 7-22 days; P < 0.002) were shorter in the buprenorphine vs. morphine group. The number of infants who received supplemental phenobarbital as adjunct therapy and the rates of adverse events were not different between the groups. These results highlight a potential new therapeutic option for infants with NAS that may decrease exposure to opioids and healthcare utilization.
STANDARDIZING INITIATION AND WEANING OF PHARMACOTHERAPY FOR NEONATAL ABSTINENCE SYNDROME
In addition to gaining a better understating of what medication is ideal when pharmacologic intervention is needed, working to standardize care across centers is of critical importance. The Vermont Oxford Network launched a 2-year multicenter quality improvement collaborative for infants with NAS in 2012 that included 199 centers. The collaborative was formed in response to the AAP policy statement released in 2012 calling for standardization of care delivered to infants with NAS [6] . In a prospective cohort study utilizing serial cross-sectional audits of participating centers, Patrick et al. [29 & ] found that among participating centers, the mean number of NAS focused guidelines increased from 3.7 to 5.1 of a possible six (P < 0.001). In addition, among infants cared for at participating centers, decreases occurred in both median length of pharmacologic treatment (16-15 days, P ¼ 0.02) and infant LOS (21 days to 19 days, P ¼ 0.002).
In addition to increased standardization of initiation of pharmacotherapy for NAS, improved strategies to wean treatment are also needed. A multicenter retrospective cohort study from the Ohio NAS research collaborative focused on the implementation of a standardized NAS weaning protocol [31] . From 2012 to 2014, 981 infants completed pharmacologic treatment for NAS with methadone or morphine in one of the six children's hospitals in Ohio. Half-way through the study period, all hospitals adopted strict guidelines for weaning opioids. At the three centers that did not previously have a guideline, the switch to a strict weaning guideline was associated with shorter duration of opioid treatment (23.0 vs. 34.0 days, P < 0.001), shorter inpatient hospitalizations (23.7 vs. 31.6 days, P < 0.001), and less adjunctive drug therapy (5 vs. 21%, P ¼ 0.004). This study highlights the benefits of a standardized weaning protocol and the role of statewide collaboration to optimize outcomes for infants with NAS.
CONCLUSION
The personal and societal burden of NAS continues to grow across the United States. Although understanding of the factors that influence disease severity have led to development of clinical prediction tools, more work is needed to discern the utility of such tools. A body of evidence has emerged describing new assessment techniques that prioritize a few functional infant signs to drive the need to treat NAS. If applied widely, these tools may drastically reduce the number of infants exposed to opioid treatment for NAS with subsequent reduction in healthcare utilization and cost. Further work is needed to identify if these modified tools can produce similar results across multiple centers. Additional research is necessary to identify the optimal medication, including dosing interval and indication for pharmacologic intervention. Lastly, state-level data and national quality improvement data are needed to identify trends in real-time and drive policy interventions aimed to address this critical public health issue. In this retrospective cohort study of maternal-infant dyads exposed to buprenorphine during pregnancy, third trimester exposure to marijuana was not significantly associated with NAS severity. 
